Colorectal Cancer Updates

Video

Insight regarding updates to the management of patients with colorectal cancer who are microsatellite instability-high (MSI-H)/mismatch repair deficient, harbor a BRAF V600E rare mutation, or have a HER2-expressing tumor.

Data from the following clinical trials is discussed:

  • Pembrolizumab vs chemotherapy for MSI-H/mismatch repair deficient metastatic colorectal cancer: The phase 3 KEYNOTE-177 study. (Andre T, et al. ASCO 2020. LBA4)

  • Encorafenib plus cetuximab +/- binimetinib for BRAF V600E metastatic colorectal cancer: BEACON CRC updated survival results (Kopetz S, et al. ASCO 2020. Abstract 4001)

  • A phase 2, multicenter, open-label study of trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): DESTINY-CRC01. (Siena S, et al. ASCO 2020. Abstract 4000)

Related Videos
Manish A. Shah, MD
Dae Won Kim, MD, Gastrointestinal Oncology Program, Moffitt Cancer Center
Michael J. Overman, MD, The University of Texas MD Anderson Cancer Center,
John Michael Bryant, MD,
Jacob Shreve, MD, MS, hematology/oncology fellow, Mayo Clinic
Efrat Dotan, MD, Fox Chase Cancer Center
A panel of 4 experts on gastrointestinal cancers
A panel of 4 experts on gastrointestinal cancers
Zev A. Wainberg, MD
A panel of 4 experts on gastrointestinal cancers